Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

Mark G. Kris, Maurizio Tonato, Emilio Bria, Enzo Ballatori, Birgitte Espersen, Jørn Herrstedt, Cynthia Rittenberg, Lawrence Einhorn, Steven Grunberg, Mitsue Saito, Gary Morrow, Paul Hesketh

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

In this update of our 2005 document, we used an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents for the prevention of emesis and nausea following anticancer chemotherapies of high emetic risk. A three-drug combination of a 5-hydroxytryptamine type 3 receptor (5-HT3) receptor antagonist, dexamethasone, and aprepitant beginning before chemotherapy and continuing for up to 4 days remains the standard of care. We address issues of dose, schedule, and route of administration of five selective 5-HT3 receptor antagonists. We conclude that, for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. In trials designed to prove the equivalence of palonosetron to ondansetron and granisetron, palonosetron proved superior in emesis prevention, while adverse effects were comparable. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration.

Original languageEnglish (US)
JournalSupportive Care in Cancer
Volume19
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 2011

Fingerprint

Emetics
Receptors, Serotonin, 5-HT3
Antiemetics
aprepitant
Nausea
Vomiting
Granisetron
Drug Therapy
Ondansetron
Drug Combinations
Standard of Care
Intravenous Administration
Appointments and Schedules
Pharmaceutical Preparations
palonosetron
Therapeutics
dexamethasone receptor

Keywords

  • Antiemetic agents
  • High-emetic-risk chemotherapy
  • Nausea

ASJC Scopus subject areas

  • Oncology

Cite this

Kris, M. G., Tonato, M., Bria, E., Ballatori, E., Espersen, B., Herrstedt, J., ... Hesketh, P. (2011). Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. Supportive Care in Cancer, 19(SUPPL. 1). https://doi.org/10.1007/s00520-010-0976-9

Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. / Kris, Mark G.; Tonato, Maurizio; Bria, Emilio; Ballatori, Enzo; Espersen, Birgitte; Herrstedt, Jørn; Rittenberg, Cynthia; Einhorn, Lawrence; Grunberg, Steven; Saito, Mitsue; Morrow, Gary; Hesketh, Paul.

In: Supportive Care in Cancer, Vol. 19, No. SUPPL. 1, 03.2011.

Research output: Contribution to journalArticle

Kris, MG, Tonato, M, Bria, E, Ballatori, E, Espersen, B, Herrstedt, J, Rittenberg, C, Einhorn, L, Grunberg, S, Saito, M, Morrow, G & Hesketh, P 2011, 'Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy', Supportive Care in Cancer, vol. 19, no. SUPPL. 1. https://doi.org/10.1007/s00520-010-0976-9
Kris, Mark G. ; Tonato, Maurizio ; Bria, Emilio ; Ballatori, Enzo ; Espersen, Birgitte ; Herrstedt, Jørn ; Rittenberg, Cynthia ; Einhorn, Lawrence ; Grunberg, Steven ; Saito, Mitsue ; Morrow, Gary ; Hesketh, Paul. / Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy. In: Supportive Care in Cancer. 2011 ; Vol. 19, No. SUPPL. 1.
@article{f3e7f71d87294a1dbf2de01556d4f1af,
title = "Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy",
abstract = "In this update of our 2005 document, we used an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents for the prevention of emesis and nausea following anticancer chemotherapies of high emetic risk. A three-drug combination of a 5-hydroxytryptamine type 3 receptor (5-HT3) receptor antagonist, dexamethasone, and aprepitant beginning before chemotherapy and continuing for up to 4 days remains the standard of care. We address issues of dose, schedule, and route of administration of five selective 5-HT3 receptor antagonists. We conclude that, for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. In trials designed to prove the equivalence of palonosetron to ondansetron and granisetron, palonosetron proved superior in emesis prevention, while adverse effects were comparable. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration.",
keywords = "Antiemetic agents, High-emetic-risk chemotherapy, Nausea",
author = "Kris, {Mark G.} and Maurizio Tonato and Emilio Bria and Enzo Ballatori and Birgitte Espersen and J{\o}rn Herrstedt and Cynthia Rittenberg and Lawrence Einhorn and Steven Grunberg and Mitsue Saito and Gary Morrow and Paul Hesketh",
year = "2011",
month = "3",
doi = "10.1007/s00520-010-0976-9",
language = "English (US)",
volume = "19",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy

AU - Kris, Mark G.

AU - Tonato, Maurizio

AU - Bria, Emilio

AU - Ballatori, Enzo

AU - Espersen, Birgitte

AU - Herrstedt, Jørn

AU - Rittenberg, Cynthia

AU - Einhorn, Lawrence

AU - Grunberg, Steven

AU - Saito, Mitsue

AU - Morrow, Gary

AU - Hesketh, Paul

PY - 2011/3

Y1 - 2011/3

N2 - In this update of our 2005 document, we used an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents for the prevention of emesis and nausea following anticancer chemotherapies of high emetic risk. A three-drug combination of a 5-hydroxytryptamine type 3 receptor (5-HT3) receptor antagonist, dexamethasone, and aprepitant beginning before chemotherapy and continuing for up to 4 days remains the standard of care. We address issues of dose, schedule, and route of administration of five selective 5-HT3 receptor antagonists. We conclude that, for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. In trials designed to prove the equivalence of palonosetron to ondansetron and granisetron, palonosetron proved superior in emesis prevention, while adverse effects were comparable. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration.

AB - In this update of our 2005 document, we used an evidence-based approach whenever possible to formulate recommendations, emphasizing the results of controlled trials concerning the best use of antiemetic agents for the prevention of emesis and nausea following anticancer chemotherapies of high emetic risk. A three-drug combination of a 5-hydroxytryptamine type 3 receptor (5-HT3) receptor antagonist, dexamethasone, and aprepitant beginning before chemotherapy and continuing for up to 4 days remains the standard of care. We address issues of dose, schedule, and route of administration of five selective 5-HT3 receptor antagonists. We conclude that, for each of these five drugs, there is a plateau in therapeutic efficacy above which further dose escalation does not improve outcome. In trials designed to prove the equivalence of palonosetron to ondansetron and granisetron, palonosetron proved superior in emesis prevention, while adverse effects were comparable. Furthermore, for all classes of antiemetic agents, a single dose is as effective as multiple doses or a continuous infusion. The oral route is as efficacious as the intravenous route of administration.

KW - Antiemetic agents

KW - High-emetic-risk chemotherapy

KW - Nausea

UR - http://www.scopus.com/inward/record.url?scp=79953297050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953297050&partnerID=8YFLogxK

U2 - 10.1007/s00520-010-0976-9

DO - 10.1007/s00520-010-0976-9

M3 - Article

C2 - 20803039

AN - SCOPUS:79953297050

VL - 19

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - SUPPL. 1

ER -